RayVa is designed to be applied as a cream to fingers or toes, delivering alprostadil directly to the area of need, in order to stimulate blood flow.
Apricus chairman, president and CEO Bassam Damaj said they are continually expanding the potential uses for NexACT and other active drugs such as alprostadil, while also attempting to bring new treatments to patients with unmet medical needs.
"Our orphan drug filing for RayVa is the second such orphan drug filing we have made in the last several years and represents another milestone for the company," Damaj said.